Belatacept, sold under the brand name Nulojix, is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4,[2] which is a molecule crucial in the regulation of T cell costimulation, selectively blocking the process of T-cell activation.

It is intended to provide extended graft and transplant[3] survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors.

It differs from abatacept (Orencia) by only two amino acids.

[medical citation needed] Belatacept was developed by Bristol-Myers-Squibb and approved by the U.S. Food and Drug Administration (FDA) on June 15, 2011.

[4] This antineoplastic or immunomodulatory drug article is a stub.